The ovarian cancer is one of the most common in women. Some molecular particles are important to stop it. Inhibitors of the enzyme poly (ADP-ribose polymerase), or PARP, in a study to stop the development of some tumours
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME July 4th 2011
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME Ovarian cancer is a malignant tumor that arises in any part of the ovary due to mutation and cell proliferation influenced by genetic, environmental or hereditary factors.
Its prognosis is good, on the rare occasions when diagnosed early Ovarian cancer is the fifth most common cancer in women in the UK, all over the world, representing approximately 4% of all cancers diagnosed in women INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME There are several genes involved in the development of this pathology as BRCA1 BRCA2 RB1 NF1 FAT3 CSMD3 GABRA6 CDK12
INTEGRATED ANALYSES OF THE OVARIAN CANCER GENOME This was determined by a genome study of women with ovarian cancer which showed mutations in the mRNA during protein synthesis
OBSERVATION I think that this is an important step in the science, because this would be the beginning of the treatment of many pathologies Understanding the genetic material allows find the answers for many medical riddles
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION July 4th 2011
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION Inhibitors of the enzyme poly (ADP-ribose) polymerase, or PARP, are among the most promising drugs currently in development as anti-tumour agents.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION BRCA1 "breast cancer 1" is a tumor suppressor gene, which regulate the cell cycle and prevent uncontrolled proliferation. CDK1 is a highly conserved protein that functions as a serine / threonine kinase, is encoded by the gene cdc2. Phosphorylation of these proteins control cell cycle progression
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION A combination of a PARP inhibitor with a Cdk1 inhibitor also showed reduced tumour growth and prolonged survival compared to treatment with one or no inhibitors in a mouse model of lung adenocarcinoma.
CDK1 INHIBITION SENSITISES TUMOURS WITH WILD TYPE BRCA1 TO PARP INHIBITION Inhibition of Cdk1 is likely to sensitise tumours with wild type BRCA1 to PARP inhibition, and that a combination of inhibitors of these two enzymes may be a useful treatment for these tumours
OBSERVATION That experiments are fundamental to know how the human life is affected begging in the littlest process that define the whole life
MEDICAL UTILITY The study of the human genome could shed any information about each individual and that is where the solution begins each pathology to develop it.
MEDICAL UTILITY New experiments with enzymes have led to cures for various types of cancer, starting with the molecular basis of such tumors which involve cell division and proper transfer of genetic information. Molecular biology is the basis for understanding the processes that lead to cause such conditions, so find a solutions or improvements to the health of people